To implement pharmacist-led, postdischarge telephone follow-up (TFU) intervention and to evaluate its impact on rehospitalization parameters in polypharmacy patients, via comparison with a well-matched control group.
Introduction
Telephone follow-up (TFU) postdischarge from hospital is a well-established approach for exchanging information with patients [1, 2] . To ensure continuity of care after hospitalization, TFU aims to provide reassurance to patients and it enables healthcare providers to detect problems at an early stage, shortly after discharge. Furthermore, it can be a channel to provide ongoing advice, reminders, educational interventions and help with symptom management [3, 4] . TFU has a number of advantages, e.g. easy to organize, economical, not time-consuming and uses technology available to all patients. It has been suggested that TFU should be more widely implemented [4] [5] [6] [7] .
To date, many research studies and several systematic reviews [1, [8] [9] [10] [11] as well as Cochrane reviews [2, 12] have examined the effectiveness of TFU. Pharmacist-led TFU has been shown to be a cost-effective method for improving medicines engagement and adherence in community settings [13, 14] . However, no robust evidence is available on the effectiveness of TFU, as an isolated intervention to reduce unplanned hospital readmission rates. TFU, in combination with other interventions, has been shown, in a number of trials, to lead to a reduction in readmission rates [15, 16] . Nevertheless, other studies showed mixed results when TFU was combined with predischarge and other postdischarge interventions [8] .
The existing hospital pharmacy led integrated medicines management (IMM) inpatient service, developed in the Antrim Area Hospital in Northern Ireland, combines pre-and postdischarge planning services to all patients.
The introduction of this IMM programme has resulted in a reduced length of hospital stay, a reduced number of readmissions post discharge, an increased time to subsequent readmission [17] and improvements in the appropriateness of medications on discharge [18] . Despite the success of the IMM programme in preventing and delaying hospital readmissions, there is still considerable room for improvement, particularly in relation to postdischarge follow-up, with an aim to reduce readmission rates [19, 20] . Accordingly, tailored patient support was delivered through TFU, where a perceptions and practicalities approach was applied [21] , as recommended by National Institute for Health and Care Excellence [22] , to influence the patient's motivation and ability to adhere to treatment recommendations. Such an intervention has the potential to have an additional impact, i.e. additive to the existing IMM service.
The objective of this research was to assess the impact of TFU on 30-day postdischarge readmission rates in polypharmacy patients who received the intervention compared with a well-matched control group within a hospital, in which IMM service provision by hospital based clinical pharmacists is a routine inpatient service. Secondary outcome measures included: 90-day readmission rates, time to readmission to hospital (if re-admitted), length of hospital stay (during the first readmission) for intervention group patients vs. matched control patients. Additional objectives were to assess the impact of TFU on a number of patient centred outcomes (intervention arm only), i.e. self-reported adherence score, adherence-related beliefs about medicines [23] and patient satisfaction. A final objective was to evaluate the economic impact of the TFU interventions.
Methods
The study was designed as a pragmatic [24, 25] , prospective, quasi-experimental study [26] , in which intervention patients were matched with a control group at a 1:1 matching ratio [27] using a propensity score matching technique [28, 29] . Ethical approval for the study was obtained from the Office for Research Ethics Committees Northern Ireland (ORECNI); reference number 14/WM/0116.
The study site was the Antrim Area Hospital, a 426-bed district general hospital within the Northern Health and Social Care Trust in Northern Ireland. Patient screening and recruitment commenced on 15 February 2016 and was completed on 30 June 2016. The follow-up period was 3 months postdischarge. The service, in the present study, was delivered by three clinical pharmacists who were members of the hospital clinical pharmacy team. Eligible patients for inclusion were adult patients aged 18 years or over who were receiving at least 10 prescribed medicines for the management of chronic illness. Patients were excluded in the following cases: suffering from a terminal illness or receiving palliative care; using a prescribed adherence support aid; unable to communicate coherently (e.g. post stroke, or severe illness that prevented communication); confused (e.g. not oriented to self, time and place); scheduled to be discharged to a nursing home, a hospice or to another hospital (rather than to own home); diagnosed with mental health illness; patients who did not manage their own medicines, i.e. totally depended on a carer for managing their medicines. In addition, patients who were alcoholic, managed by the renal disease follow-up team, or who were participating in other studies, were excluded.
A sample size calculation was carried out using sample size software (Statulator, the online beta version). Pilot study results [30] for 30-day readmission rate were used in the sample size calculation, which indicated that a sample of 175 pairs, would achieve a statistical power of 90% for detecting a 6% difference in readmission rate between intervention and control groups. A sample of 211 pairs (211 intervention patients and 211 matched control patients) was recruited to account for patients lost to follow-up.
For the patients who were eligible to join the intervention arm of the study and who, on invitation, provided written informed consent, TFU was scheduled. The clinical pharmacists involved in delivering the additional TFU service were asked to communicate with the intervention patients three times, i.e. structured telephone calls scheduled within ten days, at 1 month and at the start of the 3 rd month postdischarge. Each patient's general medical practitioner (GP) was informed of their participation in the study and a description of the new service was forwarded to them. A structured guide was employed by the clinical pharmacists during interactions with patients according to the principles of medicine optimization [20, 31] . During each interaction, the pharmacist noted any issues or problems patients were experiencing with their treatment/illness. This comprised both perceptions and practicalities; for example, they discussed adherence, any concerns patients had regarding their medicines, assessed patients' ability to manage their medication regime and provided practical individual advice to help patients overcome barriers to adherence. Interventions were documented on a record form within the following subgroups: medication adherence; health promotion; adverse event management; medical related challenges such as packaging, container and printed direction; medication supply/obtaining prescriptions; over the counter products; and, finally, patient self-evaluated health status. Moreover, patient medications were assessed and reviewed using a pharmacist outpatient medication review and recommendation template. The pharmacists contacted, as required, other health care providers (i.e. the GP, specialist nurse or community pharmacist) to facilitate resolving any issues identified.
To obtain the list of matched control patients, the following steps were carried out:
Step 1: the Charlson comorbidity index (CCI) was calculated for each recruited intervention patient [32] [33] [34] . Primary and secondary diagnoses (International Classification of Disease, ICD codes) were obtained from the hospital information system [35, 36] . The CCI was also calculated for all remaining adult patients (potential control cohort) who were admitted to the study site hospital during the study recruitment period.
Step 2: Potential matched control patients were identified for each intervention patient, i.e. having the exact values for CCI, age (in years) at discharge and sex.
Step 3: refinement of matching was carried out through a statistical matching technique, i.e. propensity score matching [28, 37] , in which a regression equation was applied to the list resulting from step 2, to obtain a propensity score for all intervention and possible control patients. The propensity score is defined as the conditional probability of assignment to a particular treatment given a vector of observed covariates. The following covariates were used in the regression equation to calculate the propensity score: number of medicines; index length of hospital stay in days; primary diagnosis; hospital ward; month of discharge.
Step 4: in the same way as for intervention patients, exclusion criteria were applied to the matched control group. Duplication was checked to avoid matching two intervention patients with the same matched control patient.
Step 5: based on the exact or nearest value of the propensity score, matching was finalised. IMM service provision for inpatients was routine across the hospital at the time the study was undertaken.
Participating intervention patients were asked to complete three different questionnaires during the study. The Medication Adherence Report Scale (MARS) and the patient Beliefs about Medicines Questionnaire (BMQ) were used to assess patient self-reported adherence and perceptions about medication (necessity beliefs and concerns) before discharge (i.e. baseline measure preintervention) and at 3 months postdischarge (i.e. after receiving the planned interventions). A bespoke patient satisfaction questionnaire was also sent (by mail 3 months postdischarge) to all participating patients, who received the planned interventions. Patients were asked in the accompanying cover letter to complete the questionnaires. A reminder telephone call was made to ensure good engagement with questionnaire completion. Figure 1 summarizes the intervention methodology.
Data collected for participating patients (administrative data on hospitalization from the hospital computer system plus data set obtained from questionnaires) were transferred to SPSS (version 23) for statistical analysis. Standard statistical methodology was used to assess the impact of postdischarge telephone follow-up by comparing data from the intervention and control groups using appropriate parametric or nonparametric tests. For the economic evaluation, cost benefit analysis was used [38, 39] .
Figure 1
Study methodology summary. *MARS, Medication Adherence Report Scale; **BMQ, Beliefs about Medicines Questionnaire
Results

Screening and recruitment
During the first 2 weeks of the study, the research team, in collaboration with the service delivery team, explored different approaches to agree on the best screening method to identify patients who were eligible to join the study. During that period, 11 patients were recruited. Figure 2 illustrates that patient screening from week 3 onwards involved 859 patients. Out of the 267 eligible patients, 200 (almost 75%) consented to participate in the study. The most frequent reasons for excluding patients were severe sickness (19%), use of prescribed adherence support products (18%) and patients not managing their own medicines (17%). Figure 1 provides details on interaction between clinical pharmacists and patients, divided into intention to treat (ITT; n = 211) and per protocol (PP; n = 131) subgroups.
Baseline patient characteristics Table 1 shows baseline patient characteristics. There were no significant differences between intervention subgroups when grouped according to the number of telephone calls received. The majority of patients enrolled in the study (66.4%) were older than 65 years. This was similar in the PP group, i.e. patients who received three telephone calls, with 60.3% of the recruited patients in this group being older than 65 years. Table S1 illustrates the reasons that prevented clinical pharmacists from fully delivering interventions to some recruited patients. The leading reason was transfer (discharge) of patients after recruitment to a destination other than their home, followed by patients who did not wish to receive further telephone calls and patients who did not respond to telephone calls.
Readmission rates
As shown in Table 2 the ITT group, when compared with the control group, demonstrated a significant reduction of 10.0% (P < 0.001) and 15.2% (P = 0.021) in the 30-day and the 90-day readmission rates respectively. The odds of readmission within 30 days and 90 days in the ITT group were reduced by 43% [odds ratio (OR) = 0.57; 95% confidence interval Figure 2 Patient participation flow. The reasons for excluding 560 patients were as follows: severe sickness terminal illness or receiving palliative care (19%, n = 106); usage of prescribed adherence support products (18%, n = 101); patients did not manage own medicines (17%, n = 95); Patient who actually used less than ten medication (13%, n = 73); scheduled to be discharged to a nursing home, a hospice or to another hospital (12%, n = 67); confused (8%, n = 45); alcoholic patients (5%, n = 28); diagnosed with mental health illness (3%, n = 17); unable to communicate coherently (2%, n = 11) managed by renal disease follow up team (2%, n = 11); patients recruited in other studies (1%, n = 6). *n = 11 patients recruited in weeks 1 and 2 of recruitment process Tables 3 and 4 illustrate the overall 30-day and 90-day readmission rate differences between intervention and control groups, taking account of the number of telephone calls received. For patients who received the scheduled three telephone calls, a significant reduction of 20.6% (P < 0.001) in 30-day readmission rate was observed compared with corresponding control group cohort. Furthermore, odds of readmission within 30 days were significantly reduced by 78% (OR = 0.22; 95% CI: 0.11-0.46). Likewise, the corresponding observed reduction in 90-day readmission rate Table 4 Subgroup analysis of readmission rate at 90-day time interval, based on number of telephone calls received by patients Time to readmission Figure 3 presents the Kaplan-Meier curve showing readmission data vs. time for the 90-day follow-up period. Estimated marginal means for time to readmission were 70.9 days (95% CI: 66.9-74.9) in the ITT group and 60.1 days (95% CI: 55.4-64.7) in the corresponding control group. This difference was statistically significant (log rank = 11.3, P = 0.001). For the subgroup of patients who received three calls (PP group), the intervention resulted in a statistically significant longer time to readmission 19.1 days (log rank = 20.0, P < 0.001), in which the estimated marginal mean for readmission in the latter intervention arm was 78.0 days (95% CI: 74.1-82.0) while it was 58.9 days (95% CI:52.9-64.9) in the control group. Censoring, (illustrated in Figure 3 ), indicated no need to carry out a death-readmission competing analysis, as all cases of death (censored subjects in the present study) were reported after readmission except in two patients as follows: one case within the control group, patient died on day 54 postdischarge and one patient in the ITT group, who received only one telephone call and died on day 77 postdischarge.
Figure 3
Kaplan-Meier curves of time to readmission Continuity of patient care post-hospitalisation
Length of hospital stay on first readmission
Compared with the control group, a significant shorter length of hospital stay on first readmission was observed for both the ITT group (8.3 days vs. 6.7 days; P < 0.001) and the PP group (7.8 days vs. 5.3 days; P < 0.001).
Economic impact
Cost benefit analysis indicated that for every pound spent on the service there will be an expected saving of £51.19 at the 30-day interval and £38.08 at the 90-day interval using the PP approach (see Tables S2 and S3 ). Likewise, there will be an expected saving of £29.62 at the 30-day interval and £23.58 at 90-day interval using the ITT approach for every pound spent on service delivery. Savings resulted from reduced readmission rates and subsequent expenses.
Questionnaire response
Within this section, only the PP data were utilized. The number of responders was 83 patients out of 131 patients who received the planned intervention (i.e. 63.4%); however, in the case of the BMQ, two forms were blank and regarding the satisfaction questionnaire three forms were not fully completed.
BMQ
The pharmacist intervention had a significant impact on patients' perceptions of their medicines. Patients receiving the intervention reported significantly higher necessityconcerns differential (NCD) scores at follow-up group (an increase of 3.8 points; 95% CI: 2.60 to 4.93; P < 0.001). This measure provides a numerical indication of how the patient judges their personal need for the medication relative to their concerns about them. NCD scores have been shown to relate to adherence across a range of long-term conditions, countries and healthcare systems [23] .
Most patients were convinced of the necessity of their medication as indicated by high scale scores at baseline. The improvement in NCD scores in the intervention group were therefore largely due to a significant reduction in medication concerns. The highest impact was noted within the concern scale in responses to the following two statements (I sometimes worry about the long-term effects of my medicines) and (Having to take medicines worries me) with a significant improvement of 43.2% (P < 0.001) and 42.7% (P < 0.001) respectively. Table 5 compares mean data for the necessity scale, the concern scale and the necessity-concern differential. Significant postintervention improvement was demonstrated in the concern scores (mean reduction of 3.2 points; 95% CI: -4.22 to À2.27; P < 0.001). Furthermore, the mean score for the necessity scale post intervention was numerically higher (by 0.6 points) than the baseline score; however, as the overall scores were high (i.e. >20) this was not statistically significant (P = 0.12).
MARS questionnaire
The intervention led to a significantly improved self-reported adherence as measured by the MARS. The mean adherence scale difference between pre-and postintervention was 1.4 (22.7 vs. 24.1; P < 0.001). Nearly one third of the 83 patients who completed the pre-and postintervention MARS questionnaires (i.e. 24 patients, 28.9%) reported the same score at baseline and post intervention. Eight patients (9.6%) responded with a lower score after the intervention. The majority of patients (51 patients, 61.4%) responded with higher scores after the intervention. Table S4 summarizes patient response to the satisfaction questionnaire, which was designed to measure the satisfaction toward each aspect of the structured intervention. The highest satisfaction levels of 92.5% and 83.8% were demonstrated in response to statements one and nine respectively, which related to easement of medicine-related problems and allowing better control of medicines respectively.
Patient satisfaction questionnaire
Discussion
To best of our knowledge this is the first pragmatic, quasiexperimental study to utilize propensity score matching to obtain a well-matched control group to determine the impact of a theory-based pharmacist-led postdischarge intervention on readmission rate. According to the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework [40, 41] pragmatic studies focus on explicit practical plans for continuation of the investigated programme after the completion of the study. Furthermore, the quasipragmatic study outcomes were meaningful to both patients and service providers rather than simply being related to the theoretical test of the investigator's hypothesis (i.e. alignment with the effectiveness criterion). The study was carried out by the hospital pharmacists based on their current qualifications and experience without tailored training (i.e. alignment with the adoption criterion) and finally the study was implemented with detailed reporting of the procedure, time allocations and costs (i.e. alignment with implementation criterion).
To mitigate against performance bias, i.e. systematic differences between groups in the care that is provided [42, 43] , detailed reasons that prevented the pharmacist from delivering the intervention as planned (i.e. three telephone calls) were recorded (Table S1 ). Moreover, ANOVA analysis confirmed that there were no differences in baseline characteristics between all subgroups. This was driven by the fact that all pairs had an exact match of the basic variables (CII, age and sex) and the final matched pairs were selected based on propensity score. Propensity score matching is considered an excellent procedure to reduce selection bias and strengthen causal argument in quasi-experimental studies [44] . It can simulate the random assignment of subjects seen in a randomized trial [29] .
The present study demonstrated a significant 30-day readmission rate reduction of 10.0% (P < 0.01) for the ITT group and 20.6% (P < 0.01) for the PP group. The results are generally in line with other studies that examined the impact of pharmacist TFU (as part of a suite of interventions) on readmission rate. For example, in a retrospective quasiexperimental study, intervention patients who received a multicomponent intervention including predischarge intervention (patient-centred, transition-focused care and medication review) and postdischarge TFU, demonstrated a 10% reduction (P = 0.04) in heart failure 30-day readmission and a 7% reduction (P = 0.43) in all-cause readmission compared with standard care patients [45] . In another quasiexperimental study, in which the control group involved simply those patients who did not receive the interventions (predischarge education, physical therapy, dietary advice and discharge planning plus postdischarge TFU and home visits in some cases) readmission rate for intervention patients was less than the control group patients during a 6-month follow-up, i.e. at the 180-day interval, readmission rate for intervention patients was reduced by 32.8% (P = 0.01) [46] .
Other studies have reported significant impact of a range of pharmacist interventions on time to readmission and length of hospital stay during the first readmission [1, 17, 19, 47, 48] . However, the present study evaluated the impact of TFU as a single intervention when provided to patients who had received routine, inpatient, IMM services. The present data therefore provide unique evidence of the value and impact of a TFU service.
To the best of our knowledge, this is the first study to present a cost-benefit analysis, including the benefit-cost ratio of the impact of TFU on readmission rate. The benefit-cost ratio in the present study was as follows: 51.19 at the 30-day interval and 38.08 at the 90-day interval for the PP approach, and 29.62 for the 30-day interval and 23.58 for the 90-day interval using the ITT approach. In this respect, the present study exhibited average savings (benefits from readmission rate reduction) of £973.37 per patient at the 90-day interval using the ITT approach. A previous study that investigated a hospital-based discharge, transition programme, led by pharmacists stated that these latter interventions resulted in an annual saving of $1034 per patient [49] , i.e. saving of a similar magnitude to the present study.
The present study had a number of limitations. Firstly, it was a single centre trial, meaning that the results may not be generalizable. Secondly, the present study considered allcause readmission. Thirdly, we were not able to verify the GP responses to recommendations made by the clinical pharmacists. Finally, the quasi-experimental design of the study was inferior to the randomized control trial design, which is considered the gold standard for clinical trials. However, a high-quality matching procedure was applied in the present study to help mitigate against this limitation and indeed such an approach can simulate the random assignment of subjects seen in a randomized trial [29] .
Conclusions
The present study clearly illustrates the benefits of a pharmacist-led intervention tailoring support to address perceptions and practicalities of regarding optimal medicines usage delivered by TFU after discharge from hospital. The intervention was provided to adult patients, receiving 10 or more prescribed medicines, by clinical pharmacists. A holistic benefit was achieved across a range of clinical, economic and humanistic outcomes. These benefits were achieved despite patients receiving structured clinical pharmacy services while in hospital, in the form of a well-established IMM service. The results suggest that this type of service should be routinely adopted in an attempt to reduce early rehospitalization of polypharmacy patients.
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